A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Dose Administration, and to Evaluate the Effect of Food After a Single Oral Dose Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs FP 025 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Foresee Pharmaceuticals
- 26 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Jul 2018.
- 26 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 04 Dec 2017 Status changed from active, no longer recruiting to completed, according to a Foresee Pharmaceuticals media release.